title: Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds.
authors.forename: Deborah
authors.initials: D
authors.lastname: Cohen
mesh_terms: D000218:Adamantane / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004151:Dipeptides / Q000009:adverse effects / Q000627:therapeutic use; D052216:Glucagon-Like Peptide 1 / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069476:Linagliptin; D010195:Pancreatitis / Q000139:chemically induced*; D011687:Purines / Q000009:adverse effects / Q000627:therapeutic use; D011719:Pyrazines / Q000009:adverse effects / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use; D014481:United States
chemical_list: D004151:Dipeptides; D007004:Hypoglycemic Agents; D011687:Purines; D011719:Pyrazines; D011799:Quinazolines; D014230:Triazoles; D000069476:Linagliptin; D052216:Glucagon-Like Peptide 1; C502994:saxagliptin; D000218:Adamantane; D000068900:Sitagliptin Phosphate